Philippines approves additive for NE treatment

The product* has been categorised as a performance enhancer that impacts feed efficiency, weight gain and lesion scores. Results from multiple research studies showed that the product consistently reduced the effects of bacteria-associated enteric disease, which has been estimated to cost the global poultry industry close to US$6 billion annually.

Lowers Clostridium perfringens-induced necrotic enteritis lesion scores

“In addition to achieving growth performance equivalent to commercial AGPs, this product has been shown to lower Clostridium perfringens-induced necrotic enteritis lesion scores, improve feed conversion, reduce mortality and support weight gain,” said Dr Ron Cravens, President, Amlan International, producer of the product. “In clinical trials, it provided a ROI of 3:1 or higher.”

Move to no antibiotics in poultry production

Interest in AGP alternatives that address bird intestinal health while enhancing performance is growing in light of the expanding global shift toward no antibiotics at all in poultry production. In clinical studies, Varium promoted broiler growth equivalent to AGPs by reducing the level of pathogens and harmful biotoxins that damage the intestinal lining, stimulating early immune function, and strengthening the intestinal barrier function.

*Varium™